Otorhinolaryngology

New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

Retrieved on: 
Thursday, February 29, 2024

These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.

Key Points: 
  • These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.
  • These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2
    This press release features multimedia.
  • More than 87% of patients responded to treatment and patients showed sustained improvement in chronic rhinitis symptoms at two years.
  • Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat and may significantly lower a person’s quality of life.

Tampa General Hospital Brings New Hope for Patients with Advanced Blood Cancers

Retrieved on: 
Monday, March 4, 2024

TAMPA, Fla., March 4, 2024 /PRNewswire/ -- As part of its commitment to harness innovative advances in cancer care, the Tampa General Hospital (TGH) Cancer Institute has added a novel approach to its therapeutic armamentarium for the treatment of patients with aggressive forms of B-cell non-Hodgkin lymphomas and other types of blood cancers.

Key Points: 
  • The field of immunotherapy has evolved from an academic research program to an essential pillar in the treatment of many cancers.
  • All are intended for the treatment of blood cancers, including lymphomas, some forms of leukemia and, most recently, multiple myeloma.
  • Following comprehensive planning and discussion, Tampa General's Hospital at Home program has started to be applied to CAR T patients meeting certain criteria.
  • Due the benefit of remote monitoring, the TGH Cancer Institute and Hospital at Home teams have been working on adapting Hospital at Home for oncology patients.

Hammes completes Silicon Valley Surgery Center in Campbell, California

Retrieved on: 
Tuesday, February 27, 2024

MILWAUKEE, Feb. 27, 2024 /PRNewswire-PRWeb/ -- Hammes, a nationally recognized leader in healthcare development, completed the development of a new ambulatory surgery center located at 2605 South Winchester Boulevard in Campbell, California. Silicon Valley Surgery Center is a joint venture between Surgery Ventures, powered by HCA Healthcare, and more than 50 multi-specialty physicians.

Key Points: 
  • Silicon Valley Surgery Center is a joint venture between Surgery Ventures, powered by HCA Healthcare, and more than 50 multi-specialty physicians.
  • We are proud to have supported the Silicon Valley Surgery Center surgeons and medical staff with a seamless transition from multiple locations to this new, conveniently located, state-of-the-art center.
  • The Silicon Valley Surgery Center team relocated from existing locations to the new, 24,000-square-foot, state-of-the-art surgery center at the end of 2023.
  • "We are proud to have supported the Silicon Valley Surgery Center surgeons and medical staff with a seamless transition from multiple locations to this new, conveniently located, state-of-the-art center," said Stephen Buckeridge, Senior Vice President of Hammes Partners.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Elevate ENT partners with Bob Glazer as Advisor to Prioritize Physician Recruiting Efforts

Retrieved on: 
Tuesday, January 23, 2024

Elevate ENT Partners (“Elevate”), a leading management service organization of ear, nose, and throat (“ENT”) practices nationwide, is pleased to announce the strategic partnership with Bob Glazer, founder of Glazer Business Advisors, to support physician recruiting initiatives.

Key Points: 
  • Elevate ENT Partners (“Elevate”), a leading management service organization of ear, nose, and throat (“ENT”) practices nationwide, is pleased to announce the strategic partnership with Bob Glazer, founder of Glazer Business Advisors, to support physician recruiting initiatives.
  • Throughout his 45-year career, Glazer held pivotal leadership roles shaping the ENT healthcare industry and brings a wealth of expertise to provide unparalleled business consultative services.
  • “In a nutshell, Elevate ENT is where passion meets purpose, and where every physician, regardless of experience, can find a home for growth and success.
  • Elevate ENT is more than a workplace; with a competitive compensation and physician led model, it is a growth hub for otolaryngologists across the nation.

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS

Retrieved on: 
Tuesday, January 16, 2024

CHICAGO, Jan. 16, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty home for physicians dedicated to cosmetic surgery and aesthetic medicine, will present its 40th Annual Scientific Meeting (ASM) on February 22-24, 2024, with an optional pre-meeting workshop on Ultrasound for Safe Brazilian Butt Lift Surgery and More, on Wednesday, February 21.

Key Points: 
  • In celebration of the AACS' 40th Annual Scientific Meeting, and the 40-year anniversary of the formation of the Academy and its official publication, The American Journal of Cosmetic Surgery, the meeting includes a comprehensive scientific program, as well as an array of advocacy, enrichment, networking and 40th anniversary celebratory activities.
  • Offering 41 educational sessions , the 2024 AACS ASM features foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery.
  • J. Kevin Duplechain, MD, FAACS, cosmetic surgeon and Immediate Past-President of the AACS and Cosmetic Surgery Foundation, will deliver the prestigious Webster Lecture on Friday, February 23.
  • Cosmetic surgery practitioners may register here for the 2024 AACS ASM.

Nearly 100 Physicians from MemorialCare's Long Beach Medical Center, Miller Children's & Women's Hospital Long Beach Recognized by Leading Doctor's Report

Retrieved on: 
Wednesday, January 3, 2024

LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.

Key Points: 
  • LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.
  • The 2023 Southern California Super Doctors report recognizes the top five percent of active doctors in Los Angeles County with two lists: Super Doctors 2023 and Rising Stars.
  • "Having our physicians listed in the Super Doctors and Rising Stars reports highlight the professionalism of our physicians who have attained a high degree of peer recognition and professional achievement," says Joe Kim, M.D., chief medical officer, MemorialCare Long Beach Medical Center.
  • "Our physicians consistently offer exceptional, quality-driven, family-centered care to our patients and families," says Graham Tse, M.D., chief medical officer, MemorialCare Miller Children's & Women's Hospital Long Beach.

ENT and Allergy Associates, LLP Strengthens Commitment to Excellence Welcomes Otolaryngologist Guy Talmor, M.D. to West Nyack, NY Office

Retrieved on: 
Thursday, December 21, 2023

With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.

Key Points: 
  • With this goal in mind, ENTA is pleased to announce the addition of Rutgers-trained otolaryngologist, Guy Talmor, M.D., to its West Nyack, NY clinical site, effective August 1st, 2024.
  • Dr. Talmor earned his Bachelor of Science degree in physiology and neuroscience from the University of California at San Diego.
  • He went on to receive his medical degree from the prestigious Keck School of Medicine of University of Southern California, graduating summa cum laude.
  • Dr. Talmor will complete his ENT residency at Rutgers New Jersey Medical School in June 2024.